
    
      PRIMARY OBJECTIVE:

      â€¢ To describe the dose limiting toxicities and adverse event profile of
      Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day for 4 weeks (1
      course).

      SECONDARYOBJECTIVE

        -  To determine the Maximum Tolerated Dose (MTD) of Camptothecin-20-O-Propionate hydrate
           (CZ48).

        -  To determine the blood plasma levels (PK study) of orally administered CZ48.

        -  To assess responses by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
           when applicable.

        -  To follow patients for survival.
    
  